Investigating the effect of adding memantine to current therapies on the symptoms of post-traumatic stress disorder
Not Applicable
Recruiting
- Conditions
- Post-traumatic stress disorder.Post-traumatic stress disorder (PTSD)F43.1
- Registration Number
- IRCT20200923048816N1
- Lead Sponsor
- Esfahan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Male and female patients with an age range of 19 to 65 years
A case of battlefield PTSD diagnosed at least 12 months in advance according to DSM 5 criteria
Exclusion Criteria
Patients with a history of dementia, schizophrenia, bipolar disorder, anxiety disorders, traumatic brain injury, and seizures according to DSM 5 criteria
Patients with a history of alcohol and psychotropic drug use in the last month or the presence of addiction in the patient's history
Patients need treatment with drugs that affect the glutamatergic system such as amantadine, dexamethasone or carbonic anhydrase inhibitors
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Symptoms of post-traumatic stress disorder. Timepoint: At the beginning of the study, the eighth week and the sixteenth week. Method of measurement: Clinical Administered PTSD Scale.
- Secondary Outcome Measures
Name Time Method